Predict your next investment

Corporation
INDUSTRIALS | Basic Materials / Specialty Chemicals
ashland.com

See what CB Insights has to offer

Investments

1

Portfolio Exits

7

Partners & Customers

10

About Ashland

Ashland (NYSE: ASH) provide specialty chemicals, technologies and insights to help customers create new and improved products for today and sustainable solutions for tomorrow. The company's chemistry is at work every day in a wide variety of markets and applications, including architectural coatings, automotive, construction, energy, food and beverage, personal care, pharmaceutical, tissue and towel, and water treatment.

Ashland Headquarter Location

8145 Blazer Drive

Wilmington, Delaware, 19808,

United States

859-815-3333

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ashland Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ashland Rank

Latest Ashland News

Sustained Release Excipients Market Growing at a CAGR of 6.8% Over the Forecast Period 2018 – 2026

May 6, 2022

Search jobs 06-May-2022 Sustained Release Excipients Market Growing at a CAGR of 6.8% Over the Forecast Period 2018 – 2026 The  sustained release excipients market  is largely dominated by local manufactures who are competing on the basis of pricing in the market.The fragmented nature of the market decreases the profitability of the business.However, growing awareness about sustained release excipients and lack of test specificity and sensitivity for sustained release excipients manufactured by local companies have increased the revenue opportunities for the global manufacturers in pharmaceutical excipients.Companies, such as BASF Corporation, Ashland Global Holdings Inc. and The Dow Chemical Company hold more than 42.8% revenue share in the global sustained release excipients market.The companies operating in the sustained release excipients market are collaborating with local distributors to increase the penetration of their products in the sustained release excipients market.Get a Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7580 Abusive Consumption of Drugs (Pain Killers) Increasing the Incidence of Chronic Diseases Across North America. Sustained release formulations are gaining popularity as they help in maintaining patient-safety through reduced number of medicine dosages, but having increased drug efficacy.From a market point of view, reduced doses improve treatment compliance, which could help higher unit sales and so their revenues.Furthermore, from the patient point of view, better therapeutic outcomes are expected due to improved drug tolerance and efficacy leading to lower switching costs and greater physician loyalty.Request Report Methodology @ https://www.futuremarketinsights.com/askus/rep-gb-7580 Increment of Diseases Across the GlobeThe prevalence of chronic as well as acute diseases is increasing across the globe. For the treatment of these diseases, doctors prescribe medicines.Medicines usually contain excipients along with the active pharmaceutical ingredients. A huge demand for medicines is witnessed because of increasing prevalence of chronic diseases.They are high in demand in Asia Pacific because of huge volume in this region.Sustained release excipients release the drug slowly so that it reaches the target site.An excipient can be used in many ways. Due to this fact it is in great demand. Sustained release excipients reduce the indirect cost associated with conventional excipients.Vertical Integration of Sustained Release Excipients Service ProvidersSustained release excipients service providers are offering their services through retail channels. Increasing innovative collaborative research opportunities in pediatric formulations is being pushed through evolution of new regulations, additional funding opportunities, and increased public-private partnerships. This has been focused to development of excipients used in all kinds of excipients such as oral solid dosage formulations and liquid pediatric formulation, which are flexible, dispersible and multi-functional. Furthermore, continued prioritization of unmet medical needs in pediatrics is expected to drive demand for these excipients and oral formulations in the forthcoming years.Ask Us Your Questions About This Report @ https://www.futuremarketinsights.com/ask-question/rep-gb-7580 Growing Impact of Drug Abuse on Public HealthSubstance abuse has high impact on the health of individuals and their families.Prolonged drug and alcohol abuse may lead to mental illness and chronic diseases, such as diabetes and heart diseases, cancer, which in turn, can create high economic burden on the society.In order to curb this economic burden caused by drug abuse, governments are focusing on prevention and early intervention strategies are expected to drive demand for drugs of abuse.For instance, according to the Centers for Disease Control and Prevention (CDC), nearly 10 million individuals aged 55 and above were reported to seek treatment for cancer across the globe. in 2014.Moreover, it is estimated that nearly US$ 600 Bn is spent on addressing the impact caused by substance abuse each year in the U.S.Competitive LandscapeCompetition section of the sustained release excipients market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings, marketing approach and company dashboard.Examples of some of the key players featured in this report include FMC Corporation, Ashland Global Holdings, BASF Corporation,The Dow Chemical Company, Roquette Freres S.A. Colorcon Inc., Croda International Inc.The key manufacturers of sustained release excipients are focusing on novel marketing strategies to increase product penetration.The companies offering point-of-care sustained release excipients are concentrating on price floor strategies.These companies are offering their products with lucrative discounts.Conventional distribution channels, such as retail pharmacies, drug stores, supermarkets and hypermarkets are expected to be the key targets channel for local manufacturers.Definition: The sustained release excipients are one of the type of excipients that are added to the drug along with active pharmaceutical ingredients of medication.Sustained release excipients are pharmacologically non-active ingredients of the drug formulation.About the Report: The report offers a comprehensive evaluation of the business opportunities prevailing in the sustained release excipients market along with insights on the sustained release excipients consumption trend, disease incidences, and awareness level for sustained release excipients and sustained release excipients market competition.The report elaborates on the macroeconomic factors influencing the dynamics of sustained release excipients market and its futuristic potential.Research MethodologyThe sustained release excipients market has been estimated based on supply-demand approach. The market was first calculated based on allergy test volume conducted in different region/countries.The test volume was estimated based on the incidence rate of various types of allergies in the top 20 countries globally.Other qualitative factors analyzed during test volume estimation include awareness level for point care sustained release excipients, the recurrence rate of allergy reaction and others.This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases).The research study on sustained release excipients market also includes top trends and macro as well as microeconomic factors shaping the sustained release excipients market.With this approach, the report on sustained release excipients market anticipates the industry attractiveness of every major segment in sustained release excipients market over the forecast period.SegmentationThe report offers a comprehensive taxonomy of sustained release excipients market based on product type, end user, route of administration route, and region. The sustained release excipients are sold for various types of test samples, such as blood, skin, etc. These sustained release excipients are used by pharmaceutical companies, biopharmaceutical companies, neutraceutical companies, and for various type of sustained release excipients, such as food allergies, drug allergies, latex allergies and other types of allergies. End-use segments in the sustained release excipients market which are a part of this sustained release excipients market report include pharmaceutical companies, biopharmaceutical companies and other end users, such as nutraceutical manufacturers and contract manufacturing organisations. The sustained release excipients market has been analyzed across regions of North America, Latin America, Europe, CIS & Russia, Asia Pacific and MEA. About Future Market Insights (FMI) Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years Contact Us:

Ashland Investments

1 Investments

Ashland has made 1 investments. Their latest investment was in Commerx as part of their Unattributed VC on December 12, 1999.

CBI Logo

Ashland Investments Activity

investments chart

Ashland Portfolio Exits

7 Portfolio Exits

Ashland has 7 portfolio exits. Their latest portfolio exit was Ashland - Performance Adhesives Business on August 31, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/31/2021

Divestiture

$99M

8

10/29/2020

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

10/9/2020

Divestiture

Subscribe to see more

Subscribe to see more

10

11/15/2018

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

2/18/2014

Divestiture

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/31/2021

10/29/2020

10/9/2020

11/15/2018

2/18/2014

Exit

Divestiture

Divestiture

Divestiture

Divestiture

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

8

10

10

10

10

Ashland Acquisitions

4 Acquisitions

Ashland acquired 4 companies. Their latest acquisition was Schulke - Personal Care Division on February 08, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/8/2021

$99M

Acquired Unit

1

1/20/2021

Subscribe to see more

$99M

Subscribe to see more

10

4/17/2017

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2006

Other Venture Capital

Subscribe to see more

$99M

Subscribe to see more

0

Date

2/8/2021

1/20/2021

4/17/2017

12/14/2006

Investment Stage

Other Venture Capital

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Total Funding

Note

Acquired Unit

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

0

Ashland Partners & Customers

10 Partners and customers

Ashland has 10 strategic partners and customers. Ashland recently partnered with Univar Solutions on April 4, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

4/12/2022

Distributor

United States

17:15 EDT Univar Solutions Expands Pharmaceutical Products Portfolio Through New Distribution Agreement with Ashland

`` Univar Solutions Inc. proudly serves pharmaceutical manufacturers and formulators through our relationships with premier suppliers like Ashland , offering the ingredients and solutions our customers are seeking for their high quality and high performing products , globally , '' said Jorge Buckup , president of Latin America for Univar Solutions Inc. .

1

9/29/2020

Distributor

Netherlands

IMCD Brasil announces new partnership with Ashland Creating a world of opportunity

IMCD announces new partnership with Ashland on speciality chemicals distribution for Personal Care and Home Care markets .

1

1/10/2020

Supplier

Netherlands

Ashland Appoints IMCD as Exclusive Channel Partner

SCHAFFHAUSEN , Switzerland - Ashland announced the extension of its global distribution agreement with IMCD , a leading distributor of specialty chemicals and food ingredients , in the coatings , construction and performance specialties businesses in Spain and Portugal .

2

7/8/2019

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

2/25/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

4/12/2022

9/29/2020

1/10/2020

7/8/2019

2/25/2019

Type

Distributor

Distributor

Supplier

Partner

Partner

Business Partner

Country

United States

Netherlands

Netherlands

Switzerland

United States

News Snippet

17:15 EDT Univar Solutions Expands Pharmaceutical Products Portfolio Through New Distribution Agreement with Ashland

`` Univar Solutions Inc. proudly serves pharmaceutical manufacturers and formulators through our relationships with premier suppliers like Ashland , offering the ingredients and solutions our customers are seeking for their high quality and high performing products , globally , '' said Jorge Buckup , president of Latin America for Univar Solutions Inc. .

IMCD Brasil announces new partnership with Ashland Creating a world of opportunity

IMCD announces new partnership with Ashland on speciality chemicals distribution for Personal Care and Home Care markets .

Ashland Appoints IMCD as Exclusive Channel Partner

SCHAFFHAUSEN , Switzerland - Ashland announced the extension of its global distribution agreement with IMCD , a leading distributor of specialty chemicals and food ingredients , in the coatings , construction and performance specialties businesses in Spain and Portugal .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Ashland Team

5 Team Members

Ashland has 5 team members, including current Senior Vice President, Keith Silverman.

Name

Work History

Title

Status

Keith Silverman

Senior Vice President

Current

William Wulfsohn

Carpenter Technology, PPG Industries, Honeywell, Rohm and Haas Company, and McKinsey & Company

Chief Executive Officer

Former

James Mish

President

Former

Philip M. Patterson

Chief Financial Officer

Former

Bob Schuetter

Chief Security Officer

Former

Name

Keith Silverman

William Wulfsohn

James Mish

Philip M. Patterson

Bob Schuetter

Work History

Carpenter Technology, PPG Industries, Honeywell, Rohm and Haas Company, and McKinsey & Company

Title

Senior Vice President

Chief Executive Officer

President

Chief Financial Officer

Chief Security Officer

Status

Current

Former

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.